Subsequent in vitro pharmacological experiments and in silico physiochemical and pharmacokinetics prediction demonstrated that the compounds D-2 and C-1, especially the compound D-2, had better pancreatic β cell protective activity via inhibition of TXNIP expression and would be promising lead candidates for the treatment of T2DM. Here, TXNIP is linked to type 2 diabetes mellitus.